BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioNJ - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://bionj.org
X-WR-CALDESC:Events for BioNJ
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241022T120000
DTEND;TZID=America/New_York:20241022T130000
DTSTAMP:20260503T045741
CREATED:20240926T131152Z
LAST-MODIFIED:20240926T131327Z
UID:12772-1729598400-1729602000@bionj.org
SUMMARY:Positioning Early Cell Therapy for Clinical Success: Mitigating Risk & Ensuring GMP Readiness
DESCRIPTION:Positioning Early Cell Therapy for Clinical Success: Mitigating Risk & Ensuring GMP Readiness\n\n\n\nTuesday\, October 22\, 2024 | 12:00 p.m.-1:00 p.m. | Virtual \n\n\n\n\nREGISTER TODAY FOR FREE!\n\n\n\n\nThe promise of cell therapies is often tempered by the many complexities of transitioning these innovations from R&D to the clinic. For early phase programs\, there are many aspects to consider\, from understanding evolving regulatory guidelines and reviewimg pathway options to addressing common manufacturing-related issues such as scalability\, high cost of goods\, and workforce retention. Additionally\, organizing and executing a successful cell therapy clinical trial can be challenged by a limited number of qualified clinical sites with experience in conducting advanced therapy studies\, access to desired Patient populations\, and managing the complex supply chain required to deliver therapies to Patients in a timely fashion. \n\n\n\nThrough a series of brief presentations on three key topic areas\, this webinar will help early phase cell therapy developers identify insights to mitigate risk and ensure clinical readiness to position their programs for success. \n\n\n\nSpecific topic areas of focus include: \n\n\n\n\nNavigating an evolving cell therapy regulatory landscape\n\n\n\nHow to assess GMP-readiness and prepare your cell therapy workflow for clinical and commercial manufacturing\n\n\n\nEnsuring patient-centricity in the complex cell therapy ecosystem and leveraging a unique\, comprehensive operating model for your product\n\n\n\n\nLearning objectives: \n\n\n\n\nStrategies to navigate regulatory hurdles and maximize impact of meetings with regulators\n\n\n\nBest practices to address common challenges in cell therapy process development and manufacturing\n\n\n\nOpportunities for a more streamlined\, Patient-centric approach to cell therapy clinical trials\n\n\n\nBenefits of working with an integrated CRO/CDMO partner to simplify the cell therapy value chain and improve Patient-centricity\n\n\n\n\nPresenters: \n\n\n\n\nMichele DugganSr. Manager\, Regulatory AffairsThermo Fisher Scientific  \n\n\n\nMs. Duggan joined Thermo Fisher Scientific in 2021 as Sr. Manager Regulatory Affairs supporting the development and delivery of regulatory solutions for customers within the biologics and advanced therapies pharma services manufacturing network. Prior to joining Thermo Fisher Scientific\, she spent over 17 years in CMC regulatory consulting\, providing regulatory strategy\, dossier authoring and review expertise for biologics and cell therapy products across all stages of the product life cycle. \n\n\n\n\n\n\n\n\n\nMindy Sadik\, Ph.D.Director\, Cell Therapy SciencesThermo Fisher Scientific  \n\n\n\nDr. Sadik oversees the Process Development and Analytical Development teams for the Cell Therapy Business unit for Advanced Therapies. Dr. Sadik’s teams work closely with partners to provide development and clinical scale services\, which include gene and non-gene modified cell processing for autologous and allogeneic cell therapies. This work includes technology transfer from the client to Thermo Fisher’s site\, process optimization and workflow readiness for transition into GMP manufacturing.  \n\n\n\n\n\n\n\n\n\nKim Watanabe\, Ph.D.Executive Director\, Cell and Gene Therapy Pillar HeadThermo Fisher Scientific  \n\n\n\nDr. Watanabe recently joined PPD\, part of Thermo Fisher Scientific\, where she leads business and operational strategy development and deployment in hematology and oncology clinical development services. She has 20 years of experience in R&D\, business and operations\, of which the last 14 years have been focused on cell and gene therapies. Prior to her current role\, Dr. Watanabe served as General Manager and Site Head for the Patheon Translational Services. Prior to her current role\, she served as GM/ Site Head for the Patheon Translational Services\, part of the contract development and manufacturing organization of Thermo Fisher Scientific. \n\n\n\n\n\n\n\n\nRegister today and join us on October 22 for this FREE educational webinar. Come ready to learn and ask questions!
URL:https://bionj.org/event/positioning-early-cell-therapy-for-clinical-success-mitigating-risk-ensuring-gmp-readiness/
LOCATION:New Jersey
END:VEVENT
END:VCALENDAR